Cargando…

Intracoronary fixed dose of nitroprusside via thrombus aspiration catheter for the prevention of the no-reflow phenomenon following primary percutaneous coronary intervention in acute myocardial infarction

Previous studies have shown that intracoronary (IC) nitroprusside (NTP) injection is a safe and effective strategy for the treatment of no-reflow (NR) during percutaneous coronary intervention (PCI). The present study tested the hypothesis that, on the basis of thrombus aspiration for the treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: ZHAO, YU-JUN, FU, XIANG-HUA, MA, XIAO-XIAO, WANG, DONG-YING, DONG, QIU-LI, WANG, YAN-BO, LI, WEI, XING, KUN, GU, XIN-SHUN, JIANG, YUN-FA
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3786843/
https://www.ncbi.nlm.nih.gov/pubmed/24137212
http://dx.doi.org/10.3892/etm.2013.1139
_version_ 1782477784454529024
author ZHAO, YU-JUN
FU, XIANG-HUA
MA, XIAO-XIAO
WANG, DONG-YING
DONG, QIU-LI
WANG, YAN-BO
LI, WEI
XING, KUN
GU, XIN-SHUN
JIANG, YUN-FA
author_facet ZHAO, YU-JUN
FU, XIANG-HUA
MA, XIAO-XIAO
WANG, DONG-YING
DONG, QIU-LI
WANG, YAN-BO
LI, WEI
XING, KUN
GU, XIN-SHUN
JIANG, YUN-FA
author_sort ZHAO, YU-JUN
collection PubMed
description Previous studies have shown that intracoronary (IC) nitroprusside (NTP) injection is a safe and effective strategy for the treatment of no-reflow (NR) during percutaneous coronary intervention (PCI). The present study tested the hypothesis that, on the basis of thrombus aspiration for the treatment of ST-segment elevation myocardial infarction (STEMI), the selective IC administration of a fixed dose of NTP (100 μg) plus tirofiban is a safe and superior treatment method compared with the IC administration of tirofiban alone for the prevention of NR during primary PCI. A total of 162 consecutive patients with STEMI, who underwent primary PCI within 12 h of onset, were randomly assigned to two groups: Group A, IC administration of a fixed dose of NTP (100 μg) plus tirofiban (10 μg/kg) and group B, IC administration of tirofiban (10 μg/kg) alone (n=80 and n=82, respectively). The drugs were selectively injected into the infarct-related artery (IRA) via a thrombus aspiration catheter advanced into the IRA. The primary end-point was post-procedural corrected thrombolysis in myocardial infarction (TIMI) frame count (CTFC). The proportion of complete (>70%) ST-segment resolution (STR); the TIMI myocardial perfusion grade (TMPG) 2–3 ratio following PCI; the peak value of creatine kinase (CK)-MB; the TIMI flow grade; the incidence of major adverse cardiac events (MACEs) and the left ventricular ejection fraction (LVEF) after 6 months of follow-up were observed as the secondary end-points. There were no significant differences in the baseline clinical and angiographic characteristics between the two groups. Compared with group B, group A had i) a lower CTFC (23±7 versus 29±11, P=0.000); ii) a higher proportion of complete STR (72.5 versus 55.9%, P=0.040); iii) an enhanced TMPG 2–3 ratio (71.3 versus 53.7%, P=0.030) and iv) a lower peak CK-MB value (170±56 versus 210±48 U/l, P=0.010). There were no statistically significant differences in the final TIMI grade-3 flow between the two groups (92.5 versus 91.5% for groups A and B, respectively; P=0.956). The LVEF at 6 months was higher in group A than group B (63±9 versus 53±11%, respectively; P=0.001); however, the incidence of MACEs was not statistically different between the two groups, although there was a trend indicating improvement in group A (log rank χ(2)=0.953, P=0.489). The selective IC administration of a fixed dose of NTP (100 μg) plus tirofiban via a thrombus aspiration catheter advanced into the IRA is a safe and superior treatment method compared with tirofiban alone in patients with STEMI undergoing primary PCI. This novel therapeutic strategy improves the myocardial level perfusion, in addition to reducing the infarct size. Furthermore, it may improve the postoperative clinical prognosis following PCI.
format Online
Article
Text
id pubmed-3786843
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-37868432013-10-17 Intracoronary fixed dose of nitroprusside via thrombus aspiration catheter for the prevention of the no-reflow phenomenon following primary percutaneous coronary intervention in acute myocardial infarction ZHAO, YU-JUN FU, XIANG-HUA MA, XIAO-XIAO WANG, DONG-YING DONG, QIU-LI WANG, YAN-BO LI, WEI XING, KUN GU, XIN-SHUN JIANG, YUN-FA Exp Ther Med Articles Previous studies have shown that intracoronary (IC) nitroprusside (NTP) injection is a safe and effective strategy for the treatment of no-reflow (NR) during percutaneous coronary intervention (PCI). The present study tested the hypothesis that, on the basis of thrombus aspiration for the treatment of ST-segment elevation myocardial infarction (STEMI), the selective IC administration of a fixed dose of NTP (100 μg) plus tirofiban is a safe and superior treatment method compared with the IC administration of tirofiban alone for the prevention of NR during primary PCI. A total of 162 consecutive patients with STEMI, who underwent primary PCI within 12 h of onset, were randomly assigned to two groups: Group A, IC administration of a fixed dose of NTP (100 μg) plus tirofiban (10 μg/kg) and group B, IC administration of tirofiban (10 μg/kg) alone (n=80 and n=82, respectively). The drugs were selectively injected into the infarct-related artery (IRA) via a thrombus aspiration catheter advanced into the IRA. The primary end-point was post-procedural corrected thrombolysis in myocardial infarction (TIMI) frame count (CTFC). The proportion of complete (>70%) ST-segment resolution (STR); the TIMI myocardial perfusion grade (TMPG) 2–3 ratio following PCI; the peak value of creatine kinase (CK)-MB; the TIMI flow grade; the incidence of major adverse cardiac events (MACEs) and the left ventricular ejection fraction (LVEF) after 6 months of follow-up were observed as the secondary end-points. There were no significant differences in the baseline clinical and angiographic characteristics between the two groups. Compared with group B, group A had i) a lower CTFC (23±7 versus 29±11, P=0.000); ii) a higher proportion of complete STR (72.5 versus 55.9%, P=0.040); iii) an enhanced TMPG 2–3 ratio (71.3 versus 53.7%, P=0.030) and iv) a lower peak CK-MB value (170±56 versus 210±48 U/l, P=0.010). There were no statistically significant differences in the final TIMI grade-3 flow between the two groups (92.5 versus 91.5% for groups A and B, respectively; P=0.956). The LVEF at 6 months was higher in group A than group B (63±9 versus 53±11%, respectively; P=0.001); however, the incidence of MACEs was not statistically different between the two groups, although there was a trend indicating improvement in group A (log rank χ(2)=0.953, P=0.489). The selective IC administration of a fixed dose of NTP (100 μg) plus tirofiban via a thrombus aspiration catheter advanced into the IRA is a safe and superior treatment method compared with tirofiban alone in patients with STEMI undergoing primary PCI. This novel therapeutic strategy improves the myocardial level perfusion, in addition to reducing the infarct size. Furthermore, it may improve the postoperative clinical prognosis following PCI. D.A. Spandidos 2013-08 2013-06-04 /pmc/articles/PMC3786843/ /pubmed/24137212 http://dx.doi.org/10.3892/etm.2013.1139 Text en Copyright © 2013, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Articles
ZHAO, YU-JUN
FU, XIANG-HUA
MA, XIAO-XIAO
WANG, DONG-YING
DONG, QIU-LI
WANG, YAN-BO
LI, WEI
XING, KUN
GU, XIN-SHUN
JIANG, YUN-FA
Intracoronary fixed dose of nitroprusside via thrombus aspiration catheter for the prevention of the no-reflow phenomenon following primary percutaneous coronary intervention in acute myocardial infarction
title Intracoronary fixed dose of nitroprusside via thrombus aspiration catheter for the prevention of the no-reflow phenomenon following primary percutaneous coronary intervention in acute myocardial infarction
title_full Intracoronary fixed dose of nitroprusside via thrombus aspiration catheter for the prevention of the no-reflow phenomenon following primary percutaneous coronary intervention in acute myocardial infarction
title_fullStr Intracoronary fixed dose of nitroprusside via thrombus aspiration catheter for the prevention of the no-reflow phenomenon following primary percutaneous coronary intervention in acute myocardial infarction
title_full_unstemmed Intracoronary fixed dose of nitroprusside via thrombus aspiration catheter for the prevention of the no-reflow phenomenon following primary percutaneous coronary intervention in acute myocardial infarction
title_short Intracoronary fixed dose of nitroprusside via thrombus aspiration catheter for the prevention of the no-reflow phenomenon following primary percutaneous coronary intervention in acute myocardial infarction
title_sort intracoronary fixed dose of nitroprusside via thrombus aspiration catheter for the prevention of the no-reflow phenomenon following primary percutaneous coronary intervention in acute myocardial infarction
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3786843/
https://www.ncbi.nlm.nih.gov/pubmed/24137212
http://dx.doi.org/10.3892/etm.2013.1139
work_keys_str_mv AT zhaoyujun intracoronaryfixeddoseofnitroprussideviathrombusaspirationcatheterforthepreventionofthenoreflowphenomenonfollowingprimarypercutaneouscoronaryinterventioninacutemyocardialinfarction
AT fuxianghua intracoronaryfixeddoseofnitroprussideviathrombusaspirationcatheterforthepreventionofthenoreflowphenomenonfollowingprimarypercutaneouscoronaryinterventioninacutemyocardialinfarction
AT maxiaoxiao intracoronaryfixeddoseofnitroprussideviathrombusaspirationcatheterforthepreventionofthenoreflowphenomenonfollowingprimarypercutaneouscoronaryinterventioninacutemyocardialinfarction
AT wangdongying intracoronaryfixeddoseofnitroprussideviathrombusaspirationcatheterforthepreventionofthenoreflowphenomenonfollowingprimarypercutaneouscoronaryinterventioninacutemyocardialinfarction
AT dongqiuli intracoronaryfixeddoseofnitroprussideviathrombusaspirationcatheterforthepreventionofthenoreflowphenomenonfollowingprimarypercutaneouscoronaryinterventioninacutemyocardialinfarction
AT wangyanbo intracoronaryfixeddoseofnitroprussideviathrombusaspirationcatheterforthepreventionofthenoreflowphenomenonfollowingprimarypercutaneouscoronaryinterventioninacutemyocardialinfarction
AT liwei intracoronaryfixeddoseofnitroprussideviathrombusaspirationcatheterforthepreventionofthenoreflowphenomenonfollowingprimarypercutaneouscoronaryinterventioninacutemyocardialinfarction
AT xingkun intracoronaryfixeddoseofnitroprussideviathrombusaspirationcatheterforthepreventionofthenoreflowphenomenonfollowingprimarypercutaneouscoronaryinterventioninacutemyocardialinfarction
AT guxinshun intracoronaryfixeddoseofnitroprussideviathrombusaspirationcatheterforthepreventionofthenoreflowphenomenonfollowingprimarypercutaneouscoronaryinterventioninacutemyocardialinfarction
AT jiangyunfa intracoronaryfixeddoseofnitroprussideviathrombusaspirationcatheterforthepreventionofthenoreflowphenomenonfollowingprimarypercutaneouscoronaryinterventioninacutemyocardialinfarction